Detailed explanation of domestic pricing and medical insurance coverage of Daridorexant

Daridorexant (Daridorexant) is a new type of dual orexin receptor antagonist. It is mainly used to treat adult insomnia and help patients improve their difficulty in falling asleep and maintaining sleep. In recent years, this drug has gained high attention in European and American countries due to its good efficacy and low risk of dependence. With the deepening of clinical research, DaliRasen has been officially approved for marketing in China, marking a further enrichment of drug options in the field of domestic insomnia treatment.

At present, the domestic pricing of DaliRasen has not been fully disclosed, but it is known that the drug has completed the listing process and has entered the purchasing catalog of some hospital pharmacies. However, because it has just been launched, the market supply is relatively limited, and it is temporarily difficult for ordinary pharmacies and e-commerce platforms to purchase it directly. DaliRasen is a self-paid drug in China and has not yet been covered by the medical insurance reimbursement policy. If patients need to take the medicine, they must bear all the costs themselves.

In foreign markets, especially Europe, the price of Dali’s original drug is about more than 2,000 yuan per box. At present, no generic drug of DaliRasen has been approved for marketing worldwide. Only the European version of the original drug is in circulation on the market, and the price is relatively stable. Since this drug is a new type of central nervous system drug, import and circulation regulations in different countries are strict, so price fluctuations are mainly affected by factors such as exchange rates and tariffs.

DaliRasen has not yet been included in China's medical insurance list, so patients will have to pay for the drug themselves in the short term. As for the situation that the domestic products have not yet been fully distributed, some patients can purchase European original drugs through formal cross-border medical or international pharmacy channels. They should pay attention to choosing legal channels and avoid purchasing drugs from unknown sources. As the market gradually matures and medical insurance negotiations advance, the drug is expected to achieve wider accessibility in the future and benefit more insomnia patients.

Reference materials:https://www.drugs.com/